Summary
Amgen Inc. announced on March 12, 2010, the successful issuance and sale of $1 billion in senior notes. This offering comprises $300 million of 4.50% Senior Notes due 2020 and $700 million of 5.75% Senior Notes due 2040. The net proceeds from this transaction are approximately $988 million and are earmarked for general corporate purposes. Investors should note that the net proceeds are allocated to a range of uses, including working capital, capital expenditures, debt service, share repurchases under existing programs, and strategic business initiatives such as acquisitions and licensing. This debt issuance is a significant financial maneuver that will impact Amgen's capital structure and future financial flexibility.
Key Highlights
- 1Amgen Inc. issued and sold a total of $1 billion in senior notes.
- 2The offering consisted of $300 million in 4.50% Senior Notes due 2020.
- 3The offering also included $700 million in 5.75% Senior Notes due 2040.
- 4Net proceeds from the offering are approximately $987,956,000 after deducting discounts and expenses.
- 5Proceeds are designated for general corporate purposes, including working capital, capital expenditures, debt service, and share repurchases.
- 6Funds will also support strategic initiatives such as acquisitions and licensing activities.
- 7The notes are unsecured and rank equally with other senior unsecured indebtedness of Amgen.
Frequently Asked Questions
This 8-K filing was primarily to report on the entry into a material definitive agreement, specifically the issuance and sale of $1 billion in senior notes by Amgen Inc.
Amgen intends to use the net proceeds of approximately $988 million for general corporate purposes. This includes working capital, capital expenditures, debt service, repayment of existing indebtedness, share repurchases, and other business initiatives like acquisitions and licensing.
The offering consists of $300 million in 4.50% Senior Notes due 2020 and $700 million in 5.75% Senior Notes due 2040. Interest is payable semi-annually, and the notes rank equally with Amgen's other senior unsecured indebtedness.
Yes, in the event of a change in control triggering event, noteholders have the right to require Amgen to purchase their notes at a price equal to 101% of the principal amount, plus accrued and unpaid interest.